Protocol
13-026
Full Title
A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients (COG ACNS1021)
Purpose
Sunitinib is approved for kidney cancer, digestive sarcoma, and pancreatic neuroendocrine tumors in adults. It works by inhibiting the development of the blood vessels that tumors need to grow and spread.
In this Children’s Oncology Group study, researchers are assessing the safety and effectiveness of sunitinib in children and young adults with high-grade gliomas and ependymomas (types of brain tumors) that have returned or continued to grow despite prior therapy. Sunitinib is a pill that is taken orally (by mouth).
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- This study is open to patients ages 1 to 21.
- Patients must have a high-grade glioma or ependymoma that has returned or continued to grow despite no more than two prior regimens of therapy.
- Patients with diffuse intrinsic pontine glioma may not participate in this study.
- Patients must have recovered from the serious side effects of previous treatments.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
For more information about this study and to inquire about eligibility, please contact Dr. Yasmin Khakoo at 212-639-8292.
Disease(s)
Brain Tumors, Primary: Gliomas
Brain Tumors, Primary: Other Trials
Pediatric Brain Tumors
Pediatric Brain Tumors: Brain Cancer
Locations
Related Diseases
